Biogen (BIIB)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-29
$253.62+1.59%
Close 2026-10-30 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-29
Research Workspace
Put BIIB beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 2% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 16%.
View QualityManagement screens strong on capital allocation, earnings delivery.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskBiogen's Growth Portfolio expansion must sustain revenue growth, with quarterly growth accelerating recently. Revenue growth reached 11% year over year in Q3 2026, following 3% in Q2. Non-GAAP earnings per share beat consensus in Q3 2026. BIIB trades at 21× P/E versus a 21× peer median. The price reflects less growth than our forecast, despite earnings yield below the sector. The multiple must be earned; our model puts the next-quarter miss probability near 13%. Peer multiples imply a price about 14% above where it trades. Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-30. BIIB is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 38 analysts currently covering BIIB (as of Oct 2026).
Based on 16 Wall Street analysts offering 12-month price targets for BIIB in the last 4 months.
Continue this research
Compare BIIB with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BIIB Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put BIIB next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete and integrate Apellis Pharmaceuticals acquisition
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $253.62
The last 12 months of price, then the range of analyst 12-month targets from today’s $253.62.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Synergy target and raised EPS reinforce acquisition integration and financial discipline.
Advances: Drive sustainable revenue growth with Growth Portfolio expansion
Reported quarterly beat and expanding growth portfolio support sustainable revenue growth.
Advances: Drive sustainable revenue growth with Growth Portfolio expansion
Rare-disease strength supports growth, though a quarterly beat is not by itself thesis-changing.
Advances: Complete and integrate Apellis Pharmaceuticals acquisition
Newly acquired drug sales support integration and growth, but do not establish durable performance.
Advances: Drive sustainable revenue growth with Growth Portfolio expansion
Estimate beat and higher guidance floor signal stronger growth and improved near-term outlook.
Advances: Drive sustainable revenue growth with Growth Portfolio expansion
Analyst optimism aligns with growth portfolio expansion.
Advances: Advance late-stage pipeline with multiple registrational data readouts
Upgrade reflects confidence in late-stage pipeline catalysts.
Advances: Drive sustainable revenue growth with Growth Portfolio expansion
Pipeline expansion aligns with revenue growth objectives.
